Skip to main content

Advertisement

SpringerLink
Log in

Lipodystrophy Is Common Among Ethiopian Patients on Highly Active Antiretroviral Therapy but Is Not Associated With Quality of Life or Medication Adherence

  • International Perspectives
  • Published:
Therapeutic Innovation & Regulatory Science Aims and scope Submit manuscript

Abstract

Clinical experience suggests that lipodystrophy (LD) can have a profound impact on quality of life (QOL) and medication adherence (MA). Thus, a hospital-based, cross-sectional study was conducted to determine the prevalence of LD and its association with QOL and MA. A total of 405 participants were included in the study. The majority of participants were female (64.5%), with a mean age of 35.69 years (SD = 9.63 years). The prevalence of LD was 30.9%. Multiple logistic regression analysis showed that type of regimen initially used is an independent predictor of severity of LD (adjusted odds ratio, 44.16; 95% confidence interval, 10.56-184.59; P =.001). Quality of life was assessed with the World Health Organization Quality of Life short form instrument (WHOQOL-BREF), and medication adherence was assessed by self-report. The mean WHOQOL-BREF score of the participants was 53.48; the highest mean value was in the domain of physical health (68.56) and the lowest was in the social relationships domain (47.09). The majority of the patients scored lower (ie, in the lowest 5 deciles) in the domains of psychological health, social relationships, and environment compared with physical health. No differences in the WHOQOL-BREF measurements were observed, except in the environment domain, between patients with moderate LD and severe LD (P =.02). The LD severity was not associated with self-reported MA (P =.42). With the exception of the psychological health domain (P =.044), participants’ WHOQOL-BREF scores were not significantly associated with MA. Lipodystrophy was not associated with QOL or MA. The prevalence of LD in the present study was within the range of previous reports; however, the mean WHOQOL-BREF score of Ethiopian patients in this study is lower compared with reports from developed countries.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hirsch HH, Battegay M. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management. Infection. 2002;30:293–298.

    CAS  PubMed  Google Scholar 

  2. Omolayo O, Sealy PL. HIV lipodystrophy syndrome. Hosp Physician. 2008;44(5):7–14.

    Google Scholar 

  3. Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. AIDS. 2001;15:1917–1930.

    CAS  PubMed  Google Scholar 

  4. Mauss S. HIV-associated lipodystrophy syndrome. AIDS. 2000;14(suppl 3):S197–S207.

    PubMed  Google Scholar 

  5. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51–F58.

    CAS  PubMed  Google Scholar 

  6. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis. 2000;30(suppl 2):S135–S142.

    CAS  PubMed  Google Scholar 

  7. Goujard C, Boufassa F, Deveaa C, et al. Incidence of clinical lipodystrophy in HIV-1 infected patients treated during primary infection. AIDS. 2001;15:282–284.

    CAS  PubMed  Google Scholar 

  8. van der Valk M, Casula M, Weverling GJ, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther. 2004;9:385–393.

    PubMed  Google Scholar 

  9. Domingo P, Cabeza MC, Pruvost A, et al. Relationship between HIV/highly active antiretroviral therapy (HAART)–associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin Infect Dis. 2010;50:1033–1040.

    CAS  PubMed  Google Scholar 

  10. Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465–471.

    CAS  PubMed  Google Scholar 

  11. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–2099.

    CAS  PubMed  Google Scholar 

  12. Schwenk A, Breuer JP, Kremer G, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study. Eur J Med Res. 2000;5(10):443–448.

    CAS  PubMed  Google Scholar 

  13. Puttawong S, Prasithsirikul W, Vadcharavivad S. Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai. 2004;87(6):605–611.

    PubMed  Google Scholar 

  14. Qaqish RB, Fisher E, Rublein J, Wohl DA. HIV associated lipodystrophy syndrome. Pharmacotherapy. 2000;20:13–22.

    CAS  PubMed  Google Scholar 

  15. Reus S, Arroyo E, Boix V, Portilla J. Lipodystrophy and hyperglycemia produced by protease inhibitors. Ann Med Intern. 2000;17:123–126.

    CAS  Google Scholar 

  16. Behrens G, Schmidt RW. Lipodystrophy syndrome. Published 2011. http://hivbook.com/2011/10/23/lipodystrophy-syndrome/.

  17. VanGriensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hygiene. 2007;101(8):793–798.

    Google Scholar 

  18. Womack J. HIV-related lipodystrophy in Africa and Asia. AIDS Reader. 2009;19:131–139, 148–152.

    PubMed  Google Scholar 

  19. van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847–855.

    PubMed  Google Scholar 

  20. Grunfeld C, Kotler DP, Arnett DK, et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation. 2008;118(2):e20–e28.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Mutimura E, Stewart A, Crowther NJ. Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther. 2007;4:19.

    PubMed  PubMed Central  Google Scholar 

  22. Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader. 2000;10:546–550.

    CAS  PubMed  Google Scholar 

  23. The EuroQol Group. EuroQola new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.

    Google Scholar 

  24. Silva CG, Alchieri JC. Esthetic self-perception of HIV/AIDS patients under antiretroviral therapy suffering from lipodystrophic syndrome and its influence on the quality of life in a city of the Brazilian northeast. J Public Health Epidemiol. 2011;3(11):529–535.

    Google Scholar 

  25. Noerholm V, Groenvold M, Watt T, Bjorner JB, Rasmussen NA, Bech P. Quality of life in the Danish general population—normative data and validity of WHOQOLBREF using Rasch and item response theory models. Qual Life Res. 2004;13:531–540.

    CAS  PubMed  Google Scholar 

  26. Blanch J, Rousaud A, Martýnez E, et al. Impact of lipodystrophy on the quality of life of HIV-1–infected patients. J Acquir Immune Defic Syndr. 2002;31:404–407.

    CAS  PubMed  Google Scholar 

  27. Burgoyne R, Collins E, Wagner C, et al. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res. 2005;14:981–990.

    PubMed  Google Scholar 

  28. Guaraldi G, Murri R, Orlando G, et al. Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS. 2008;22(7):577–585.

    PubMed  PubMed Central  Google Scholar 

  29. Duran SA, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441–2444.

    CAS  PubMed  Google Scholar 

  30. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr. 2002;31:S140–S144.

    PubMed  Google Scholar 

  31. Tien PC, Barron Y, Justman JE, et al. Antiretroviral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDS. 2007;21:297–305.

    PubMed  PubMed Central  Google Scholar 

  32. Corless IB, Kirksey KM, Kemppainen J, et al. Lipodystrophy-associated symptoms and medication adherence in HIV/AIDS. AIDS Patient Care STDS. 2005;19(9):577–586.

    PubMed  Google Scholar 

  33. Mannheimer SB, Matts J, Telzak E, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005;17(1):10–22.

    CAS  PubMed  Google Scholar 

  34. Oette M, Juretzko P, Kroidl A, et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDS. 2002;16:413–417.

    PubMed  Google Scholar 

  35. Reynolds NR, Neidig JL, Wu AW, et al. Balancing disfigurement and fear of disease progression: patient perceptions of HIV body fat redistribution. AIDS Care. 2006;18:663–673.

    CAS  PubMed  Google Scholar 

  36. World Health Organization Programme on Mental Health. WHOQOL-BREF: Introduction, Administration, Scoring and Generic Version of the Assessment. Geneva, Switzerland: World Health Organization; 1996.

    Google Scholar 

  37. Martinez E, Mocroft A, García-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357(9256):592–598.

    CAS  PubMed  Google Scholar 

  38. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med. 2001;2:174–180.

    CAS  PubMed  Google Scholar 

  39. Mallal S, John M, Moore C, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in HIV infection. AIDS. 2000;14:1309–1316.

    CAS  PubMed  Google Scholar 

  40. Domingo P, Cabeza MC, Pruvost A, et al. Relationship between HIV/highly active antiretroviral therapy (HAART)–associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin Infect Dis. 2010;50:1033–1040.

    CAS  PubMed  Google Scholar 

  41. Chêne G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis. 2002;34(5):649–657.

    PubMed  Google Scholar 

  42. Noerholm V, Groenvold M, Watt T, Bjorner JB, Rasmussen NA, Bech P. Quality of life in the Danish general population—normative data and validity of WHOQOLBREF using Rasch and item response theory models. Qual Life Res. 2004;13:531–540.

    CAS  PubMed  Google Scholar 

  43. Blanch J, Rousaud A, Martýnez E, et al. Impact of lipodystrophy on the quality of life of HIV-1–infected patients. J Acquir Immune Defic Syndr. 2002;31:404–407.

    CAS  PubMed  Google Scholar 

  44. Schrooten W, Colebunders R, Youle M, et al. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS. 2001;15:1019–1023.

    CAS  PubMed  Google Scholar 

  45. Dukers N, Stolte IG, Albrecht N, et al. The impact of experiencing lipodystrophy on the sexual behavior and well-being among HIV infected homosexual men. AIDS. 2001;15:812–813.

    CAS  PubMed  Google Scholar 

  46. Guaraldi G, Luzi K, Murri R, et al. Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Antiviral Ther. 2007;12:1059–1065.

    Google Scholar 

  47. Duran SA, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441–2444.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Jimma, Ethiopia

    Nasir Tajure Wabe BPharm, MSc

  2. Clinical Pharmacy Unit, Department of Pharmacy, College of Public Health and Medical Science, Jimma University, Jimma, Ethiopia

    Nezif Hussien Dekama BPharm, MSc

  3. Department of Epidemiology, College of Public Health and Medical Science, Jimma University, Jimma, Ethiopia

    Desta Hiko Gemeda BSc, MPH

Authors
  1. Nasir Tajure Wabe BPharm, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nezif Hussien Dekama BPharm, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Desta Hiko Gemeda BSc, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nasir Tajure Wabe BPharm, MSc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wabe, N.T., Dekama, N.H. & Gemeda, D.H. Lipodystrophy Is Common Among Ethiopian Patients on Highly Active Antiretroviral Therapy but Is Not Associated With Quality of Life or Medication Adherence. Ther Innov Regul Sci 47, 706–714 (2013). https://doi.org/10.1177/2168479013500967

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1177/2168479013500967

Keywords

Search

Navigation